{"id":"abivertinib-maleate-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abivertinib selectively inhibits epidermal growth factor receptor (EGFR) tyrosine kinase, particularly mutations associated with non-small cell lung cancer. By blocking EGFR signaling, it prevents downstream activation of proliferation and survival pathways in cancer cells. The drug is designed to overcome certain resistance mechanisms in EGFR-mutant tumors.","oneSentence":"Abivertinib is a tyrosine kinase inhibitor that targets mutant EGFR and other kinases involved in cancer cell proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:40.848Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer with EGFR mutations"}]},"trialDetails":[{"nctId":"NCT04440007","phase":"PHASE2","title":"Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19","status":"COMPLETED","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2020-10-09","conditions":"Covid-19","enrollment":96},{"nctId":"NCT04528667","phase":"PHASE2","title":"Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19","status":"COMPLETED","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2021-01-06","conditions":"Covid19","enrollment":396},{"nctId":"NCT03856697","phase":"PHASE3","title":"Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation","status":"UNKNOWN","sponsor":"Hangzhou ACEA Pharmaceutical Research Co., Ltd.","startDate":"2019-03","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":406}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Abivertinib Maleate Capsules","genericName":"Abivertinib Maleate Capsules","companyName":"Hangzhou ACEA Pharmaceutical Research Co., Ltd.","companyId":"hangzhou-acea-pharmaceutical-research-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abivertinib is a tyrosine kinase inhibitor that targets mutant EGFR and other kinases involved in cancer cell proliferation. Used for Non-small cell lung cancer with EGFR mutations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}